<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596840</url>
  </required_header>
  <id_info>
    <org_study_id>B2018-106</org_study_id>
    <nct_id>NCT03596840</nct_id>
  </id_info>
  <brief_title>Community-based Microalbuminuria Screening in Patients With Hypertension</brief_title>
  <acronym>CMSIH</acronym>
  <official_title>Effectiveness of Different Antihypertensive Medications on Urine Albumin-to-Creatinine Ratio (UACR) in Community Hypertensive Patients With Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness of different anti-hypertensive drugs on patients with
      hypertension and microalbuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a a real world registry study. All patients with hypertension in community hospitals
      in China will be eligible . Patient demographics, medical history, clinical characteristics,
      physical examination, laboratory tests (including UCAR, blood routine, urine routine, blood
      biochemistry, and ECG), antihypertensive drugs (including: ACEI/ ARB, thiazide diuretics,
      CCB, beta-blockers, alpha-blockers, and other antihypertensive drugs used in real-life
      clinical practice in other communities.) will be recorded. All patients are anticipated to be
      followed up for 12-month. Effectiveness of different antihypertensive medications on Urine
      Albumin-to-Creatinine Ratio (UACR) will be evaluted.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Albumin-to-Creatinine Ratio (UCAR)</measure>
    <time_frame>12 months</time_frame>
    <description>Differences in UCAR between with ACEI/ARB and without ACEI/ARB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined endpoints: re-admission, cardiovascular events, and all-cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Differences in Combined endpoints between with ACEI/ARB and without ACEI/ARB</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hypertension</condition>
  <condition>Microalbuminuria</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Community Hypertensive Patients With Microalbuminuria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with essential hypertension;

          -  Urinary albumin/creatinine ratio in random urine samples is 30-300 mg/g

          -  Age &gt;=18

          -  Understand and sign informed consent

        Exclusion Criteria:

          -  This is a real-world registry study and does not set exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuejuan Jin, MS</last_name>
    <phone>+86-13681973269</phone>
    <email>jin.xuejuan@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Zhang, phD</last_name>
    <phone>+86-13917535963</phone>
  </overall_contact_backup>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Xuejuan Jin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Microalbuminuria</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Antihypertensive medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

